Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cancer Cell International
Published in: Cancer Cell International 1/2010

Open Access 01-12-2010 | Review

Novel molecular imaging platform for monitoring oncological kinases

Authors: Shyam Nyati, Brian D Ross, Alnawaz Rehemtulla, Mahaveer S Bhojani

Published in: Cancer Cell International | Issue 1/2010

Login to get access

Abstract

Recent advances in oncology have lead to identification of a plethora of alterations in signaling pathways that are critical to oncogenesis and propagation of malignancy. Among the biomarkers identified, dysregulated kinases and associated changes in signaling cascade received the lion's share of scientific attention and have been under extensive investigations with goal of targeting them for anti-cancer therapy. Discovery of new drugs is immensely facilitated by molecular imaging technology which enables non-invasive, real time, dynamic imaging and quantification of kinase activity. Here, we review recent development of novel kinase reporters based on conformation dependent complementation of firefly luciferase to monitor kinase activity. Such reporter system provides unique insights into the pharmacokinetics and pharmacodynamics of drugs that modulate kinase signaling and have a huge potential in drug discovery, validation, and drug-target interactions.
Appendix
Available only for authorised users
Literature
1.
Sara H, Kallioniemi O, Nees M: A decade of cancer gene profiling: from molecular portraits to molecular function. Methods in molecular biology (Clifton, NJ). 576: 61-87. full_text.
2.
Camp RL, Neumeister V, Rimm DL: A decade of tissue microarrays: progress in the discovery and validation of cancer biomarkers. J Clin Oncol. 2008, 26 (34): 5630-5637. 10.1200/JCO.2008.17.3567.CrossRefPubMed
3.
van de Rijn M, Gilks CB: Applications of microarrays to histopathology. Histopathology. 2004, 44 (2): 97-108. 10.1111/j.1365-2559.2004.01766.x.CrossRefPubMed
4.
5.
Sotiriou C, Piccart MJ: Taking gene-expression profiling to the clinic: when will molecular signatures become relevant to patient care?. Nat Rev Cancer. 2007, 7 (7): 545-553. 10.1038/nrc2173.CrossRefPubMed
6.
Gazdar AF: Epidermal growth factor receptor inhibition in lung cancer: the evolving role of individualized therapy. Cancer Metastasis Rev. 2010, 29 (1): 37-48. 10.1007/s10555-010-9201-z.PubMedCentralCrossRefPubMed
7.
Baselga J: The EGFR as a target for anticancer therapy--focus on cetuximab. Eur J Cancer. 2001, 37 (Suppl 4): S16-22. 10.1016/S0959-8049(01)00233-7.CrossRefPubMed
8.
Grunwald V, Hidalgo M: Developing inhibitors of the epidermal growth factor receptor for cancer treatment. J Natl Cancer Inst. 2003, 95 (12): 851-867. 10.1093/jnci/95.12.851.CrossRefPubMed
9.
Haas-Kogan DA, Prados MD, Tihan T, Eberhard DA, Jelluma N, Arvold ND, Baumber R, Lamborn KR, Kapadia A, Malec M: Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. J Natl Cancer Inst. 2005, 97 (12): 880-887. 10.1093/jnci/dji161.CrossRefPubMed
10.
Giaccone G: HER1/EGFR-targeted agents: predicting the future for patients with unpredictable outcomes to therapy. Ann Oncol. 2005, 16 (4): 538-548. 10.1093/annonc/mdi129.CrossRefPubMed
11.
Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science (New York, NY). 2004, 304 (5676): 1497-1500.CrossRef
12.
Ross JS, Slodkowska EA, Symmans WF, Pusztai L, Ravdin PM, Hortobagyi GN: The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist. 2009, 14 (4): 320-368. 10.1634/theoncologist.2008-0230.CrossRefPubMed
13.
Weissleder R, D RB, Rehemtulla A, Gambhir SS: Molecular Imaging, Principles and Practice. Shelton, Connecticut, USA: People's Medical Publishing House-USA. 2010
14.
Bhojani MS, Ross BD, Rehemtulla A: Imaging of signaling pathways. Molecular Imaging, Priniciples and Practice. Edited by: Weissleder R, D RB, Rehemtulla A, Gambhir SS. 2010, People's Medical Publishing House-USA, Shelton, CT, USA, 829-841.
15.
Weissleder R, Ntziachristos V: Shedding light onto live molecular targets. Nature medicine. 2003, 9 (1): 123-128. 10.1038/nm0103-123.CrossRefPubMed
16.
Mahmood U, Weissleder R: Near-infrared optical imaging of proteases in cancer. Mol Cancer Ther. 2003, 2 (5): 489-496.PubMed
17.
Gelovani Tjuvajev J, Blasberg RG: In vivo imaging of molecular-genetic targets for cancer therapy. Cancer Cell. 2003, 3 (4): 327-332. 10.1016/S1535-6108(03)00082-5.CrossRefPubMed
18.
Chenevert TL, Stegman LD, Taylor JM, Robertson PL, Greenberg HS, Rehemtulla A, Ross BD: Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors. J Natl Cancer Inst. 2000, 92 (24): 2029-2036. 10.1093/jnci/92.24.2029.CrossRefPubMed
19.
Moffat BA, Hall DE, Stojanovska J, McConville PJ, Moody JB, Chenevert TL, Rehemtulla A, Ross BD: Diffusion imaging for evaluation of tumor therapies in preclinical animal models. Magma. 2004, 17 (3-6): 249-259. 10.1007/s10334-004-0079-z.CrossRefPubMed
20.
Guccione S, Li KC, Bednarski MD: Molecular imaging and therapy directed at the neovasculature in pathologies. How imaging can be incorporated into vascular-targeted delivery systems to generate active therapeutic agents. IEEE Eng Med Biol Mag. 2004, 23 (5): 50-56. 10.1109/MEMB.2004.1360408.CrossRefPubMed
21.
Morgan B, Horsfield MA, Steward WP: The role of imaging in the clinical development of antiangiogenic agents. Hematol Oncol Clin North Am. 2004, 18 (5): 1183-1206. 10.1016/j.hoc.2004.06.011. xCrossRefPubMed
22.
Contag CH, Bachmann MH: Advances in in vivo bioluminescence imaging of gene expression. Annu Rev Biomed Eng. 2002, 4: 235-260. 10.1146/annurev.bioeng.4.111901.093336.CrossRefPubMed
23.
Bremer C, Ntziachristos V, Weissleder R: Optical-based molecular imaging: contrast agents and potential medical applications. Eur Radiol. 2003, 13 (2): 231-243.PubMed
24.
Bhaumik S, Gambhir SS: Optical imaging of Renilla luciferase reporter gene expression in living mice. Proceedings of the National Academy of Sciences of the United States of America. 2002, 99 (1): 377-382. 10.1073/pnas.012611099.PubMedCentralCrossRefPubMed
25.
Ross BD, Chenevert TL, Rehemtulla A: Magnetic resonance imaging in cancer research. Eur J Cancer. 2002, 38 (16): 2147-2156. 10.1016/S0959-8049(02)00387-8.CrossRefPubMed
26.
Blasberg R: PET imaging of gene expression. Eur J Cancer. 2002, 38 (16): 2137-2146. 10.1016/S0959-8049(02)00390-8.CrossRefPubMed
27.
Blasberg RG, Gelovani J: Molecular-genetic imaging: a nuclear medicine-based perspective. Mol Imaging. 2002, 1 (3): 280-300. 10.1162/153535002760235472.CrossRefPubMed
28.
Alavi A, Lakhani P, Mavi A, Kung JW, Zhuang H: PET: a revolution in medical imaging. Radiol Clin North Am. 2004, 42 (6): 983-1001. 10.1016/j.rcl.2004.08.012. viiCrossRefPubMed
29.
Bhojani MS, Laxman B, Ross BD, Rehemtulla A: Molecular Imaging in Cancer. Apoptosis and Cancer Therapy. Edited by: DKMaF S. 2006, Weinheim: Wiley-VCH, II: 37-59.
30.
Zhang L, Bhojani MS, Ross BD, Rehemtulla A: Molecular imaging of protein kinases. Cell cycle (Georgetown, Tex). 2008, 7 (3): 314-317. 10.4161/cc.7.3.5409.CrossRef
31.
Gross S, Piwnica-Worms D: Spying on cancer: molecular imaging in vivo with genetically encoded reporters. Cancer Cell. 2005, 7 (1): 5-15.PubMed
32.
Narula J, Kietselaer B, Hofstra L: Role of molecular imaging in defining and denying death. J Nucl Cardiol. 2004, 11 (3): 349-357. 10.1016/j.nuclcard.2004.03.008.CrossRefPubMed
33.
Greer LF, Szalay AA: Imaging of light emission from the expression of luciferases in living cells and organisms: a review. Luminescence. 2002, 17 (1): 43-74. 10.1002/bio.676.CrossRefPubMed
34.
Contag CH, Ross BD: It's not just about anatomy: in vivo bioluminescence imaging as an eyepiece into biology. J Magn Reson Imaging. 2002, 16 (4): 378-387. 10.1002/jmri.10178.CrossRefPubMed
35.
Rehemtulla A, Stegman LD, Cardozo SJ, Gupta S, Hall DE, Contag CH, Ross BD: Rapid and quantitative assessment of cancer treatment response using in vivo bioluminescence imaging. Neoplasia (New York, NY). 2000, 2 (6): 491-495.CrossRef
36.
Ciana P, Raviscioni M, Mussi P, Vegeto E, Que I, Parker MG, Lowik C, Maggi A: In vivo imaging of transcriptionally active estrogen receptors. Nature medicine. 2003, 9 (1): 82-86. 10.1038/nm809.CrossRefPubMed
37.
Carlsen H, Moskaug JO, Fromm SH, Blomhoff R: In vivo imaging of NF-kappa B activity. J Immunol. 2002, 168 (3): 1441-1446.CrossRefPubMed
38.
Doubrovin M, Ponomarev V, Beresten T, Balatoni J, Bornmann W, Finn R, Humm J, Larson S, Sadelain M, Blasberg R: Imaging transcriptional regulation of p53-dependent genes with positron emission tomography in vivo. Proceedings of the National Academy of Sciences of the United States of America. 2001, 98 (16): 9300-9305. 10.1073/pnas.161091198.PubMedCentralCrossRefPubMed
39.
Rehemtulla A, Taneja N, Ross BD: Bioluminescence detection of cells having stabilized p53 in response to a genotoxic event. Mol Imaging. 2004, 3 (1): 63-68. 10.1162/153535004773861732.CrossRefPubMed
40.
Laxman B, Hall DE, Bhojani MS, Hamstra DA, Chenevert TL, Ross BD, Rehemtulla A: Noninvasive real-time imaging of apoptosis. Proceedings of the National Academy of Sciences of the United States of America. 2002, 99 (26): 16551-16555. 10.1073/pnas.252644499.PubMedCentralCrossRefPubMed
41.
Luker GD, Sharma V, Pica CM, Prior JL, Li W, Piwnica-Worms D: Molecular imaging of protein-protein interactions: controlled expression of p53 and large T-antigen fusion proteins in vivo. Cancer research. 2003, 63 (8): 1780-1788.PubMed
42.
Papadakis ED, Nicklin SA, Baker AH, White SJ: Promoters and control elements: Designing expression cassettes for gene therapy. Current Gene Therapy. 2004, 4 (1): 89-113. 10.2174/1566523044578077.CrossRefPubMed
43.
Ray P, De A, Min JJ, Tsien RY, Gambhir SS: Imaging tri-fusion multimodality reporter gene expression in living subjects. Cancer research. 2004, 64 (4): 1323-1330. 10.1158/0008-5472.CAN-03-1816.PubMedCentralCrossRefPubMed
44.
Sadeghi H, Hitt MA: Transcriptionally targeted adenovirus vectors. Current Gene Therapy. 2005, 5 (4): 411-427. 10.2174/1566523054546189.CrossRefPubMed
45.
Jaffer FA, Tung CH, Gerszten RE, Weissleder R: In vivo Imaging of thrombin activity in experimental thrombi with thrombin-sensitive near-infrared molecular probe. Arteriosclerosis Thrombosis and Vascular Biology. 2002, 22 (11): 1929-1935. 10.1161/01.ATV.0000033089.56970.2D.CrossRef
46.
Livet J, Weissman TA, Kang HN, Draft RW, Lu J, Bennis RA, Sanes JR, Lichtman JW: Transgenic strategies for combinatorial expression of fluorescent proteins in the nervous system. Nature. 2007, 450 (7166): 56-10.1038/nature06293.CrossRefPubMed
47.
Fields S, Song O: A novel genetic system to detect protein-protein interactions. Nature. 1989, 340 (6230): 245-246. 10.1038/340245a0.CrossRefPubMed
48.
Hu CD, Chinenov Y, Kerppola TK: Visualization of interactions among bZIP and Rel family proteins in living cells using bimolecular fluorescence complementation. Mol Cell. 2002, 9 (4): 789-798. 10.1016/S1097-2765(02)00496-3.CrossRefPubMed
49.
Luker GD, Sharma V, Pica CM, Dahlheimer JL, Li W, Ochesky J, Ryan CE, Piwnica-Worms H, Piwnica-Worms D: Noninvasive imaging of protein-protein interactions in living animals. Proceedings of the National Academy of Sciences of the United States of America. 2002, 99 (10): 6961-6966. 10.1073/pnas.092022399.PubMedCentralCrossRefPubMed
50.
Luker KE, Piwnica-Worms D: Optimizing luciferase protein fragment complementation for bioluminescent imaging of protein-protein interactions in live cells and animals. Methods in enzymology. 2004, 385: 349-360. full_text.CrossRefPubMed
51.
Galarneau A, Primeau M, Trudeau LE, Michnick SW: Beta-lactamase protein fragment complementation assays as in vivo and in vitro sensors of protein protein interactions. Nature biotechnology. 2002, 20 (6): 619-622. 10.1038/nbt0602-619.CrossRefPubMed
52.
Michnick SW, Ear PH, Manderson EN, Remy I, Stefan E: Universal strategies in research and drug discovery based on protein-fragment complementation assays. Nature reviews. 2007, 6 (7): 569-582. 10.1038/nrd2311.PubMed
53.
Remy I, Michnick SW: A highly sensitive protein-protein interaction assay based on Gaussia luciferase. Nat Methods. 2006, 3 (12): 977-979. 10.1038/nmeth979.CrossRefPubMed
54.
Remy I, Michnick SW: Application of protein-fragment complementation assays in cell biology. Biotechniques. 2007, 42 (2): 137-10.2144/000112396. 139, 141 passimCrossRefPubMed
55.
Paulmurugan R, Gambhir SS: Monitoring protein-protein interactions using split synthetic renilla luciferase protein-fragment-assisted complementation. Anal Chem. 2003, 75 (7): 1584-1589. 10.1021/ac020731c.PubMedCentralCrossRefPubMed
56.
Li WR, Li F, Huang Q, Frederick B, Bao SD, Li CY: Noninvasive imaging and quantification of epidermal growth factor receptor kinase activation in vivo. Cancer research. 2008, 68 (13): 4990-4997. 10.1158/0008-5472.CAN-07-5984.PubMedCentralCrossRefPubMed
57.
Zhang L, Lee KC, Bhojani MS, Khan AP, Shilman A, Holland EC, Ross BD, Rehemtulla A: Molecular imaging of Akt kinase activity. Nature medicine. 2007, 13 (9): 1114-1119. 10.1038/nm1608.CrossRefPubMed
58.
Zhang L, Bhojani MS, Ross BD, Rehemtulla A: Enhancing Akt imaging through targeted reporter expression. Mol Imaging. 2008, 7 (4): 168-174.PubMedCentralPubMed
59.
Coppola JM, Ross BD, Rehemtulla A: Noninvasive imaging of apoptosis and its application in cancer therapeutics. Clin Cancer Res. 2008, 14 (8): 2492-2501. 10.1158/1078-0432.CCR-07-0782.PubMedCentralCrossRefPubMed
60.
Manning G, Plowman GD, Hunter T, Sudarsanam S: Evolution of protein kinase signaling from yeast to man. Trends in biochemical sciences. 2002, 27 (10): 514-520. 10.1016/S0968-0004(02)02179-5.CrossRefPubMed
61.
Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S: The protein kinase complement of the human genome. Science (New York, NY). 2002, 298 (5600): 1912-1934.CrossRef
62.
Edelman AM, Blumenthal DK, Krebs EG: Protein serine/threonine kinases. Annual review of biochemistry. 1987, 56: 567-613.CrossRefPubMed
63.
Hubbard SR, Till JH: Protein tyrosine kinase structure and function. Annual review of biochemistry. 2000, 69: 373-398. 10.1146/annurev.biochem.69.1.373.CrossRefPubMed
64.
65.
Tsygankov AY: Non-receptor protein tyrosine kinases. Front Biosci. 2003, 8: s595-635. 10.2741/1106.CrossRefPubMed
66.
Blume-Jensen P, Hunter T: Oncogenic kinase signalling. Nature. 2001, 411 (6835): 355-365. 10.1038/35077225.CrossRefPubMed
67.
Ben-Bassat H: Biological activity of tyrosine kinase inhibitors: novel agents for psoriasis therapy. Curr Opin Investig Drugs. 2001, 2 (11): 1539-1545.PubMed
68.
Blease K: Targeting kinases in asthma. Expert opinion on investigational drugs. 2005, 14 (10): 1213-1220. 10.1517/13543784.14.10.1213.CrossRefPubMed
69.
Kumar R, Singh VP, Baker KM: Kinase inhibitors for cardiovascular disease. J Mol Cell Cardiol. 2007, 42 (1): 1-11. 10.1016/j.yjmcc.2006.09.005.CrossRefPubMed
70.
Mueller BK, Mack H, Teusch N: Rho kinase, a promising drug target for neurological disorders. Nature reviews. 2005, 4 (5): 387-398. 10.1038/nrd1719.PubMed
71.
Westra J, Limburg PC: p38 mitogen-activated protein kinase (MAPK) in rheumatoid arthritis. Mini Rev Med Chem. 2006, 6 (8): 867-874. 10.2174/138955706777934982.CrossRefPubMed
72.
73.
Bailey HH, Mahoney MR, Ettinger DS, Maples WJ, Fracasso PM, Traynor AM, Erlichman C, Okuno SH: Phase II study of daily oral perifosine in patients with advanced soft tissue sarcoma. Cancer. 2006, 107 (10): 2462-2467. 10.1002/cncr.22308.CrossRefPubMed
74.
Vink SR, Schellens JH, Beijnen JH, Sindermann H, Engel J, Dubbelman R, Moppi G, Hillebrand MJ, Bartelink H, Verheij M: Phase I and pharmacokinetic study of combined treatment with perifosine and radiation in patients with advanced solid tumours. Radiother Oncol. 2006, 80 (2): 207-213. 10.1016/j.radonc.2006.07.032.CrossRefPubMed
75.
Chan TO, Rittenhouse SE, Tsichlis PN: AKT/PKB and other D3 phosphoinositide-regulated kinases: kinase activation by phosphoinositide-dependent phosphorylation. Annual review of biochemistry. 1999, 68: 965-1014. 10.1146/annurev.biochem.68.1.965.CrossRefPubMed
76.
Cantley LC: The phosphoinositide 3-kinase pathway. Science (New York, NY). 2002, 296 (5573): 1655-1657.CrossRef
77.
Nyati S, Ranga R, Ross BD, Rehemtulla A, MS B: Molecular Imaging of GSK3β and CK1α kinases. Analytical Biochemistry. 2010,
78.
Cohen P, Knebel A: KESTREL: a powerful method for identifying the physiological substrates of protein kinases. The Biochemical journal. 2006, 393 (Pt 1): 1-6.PubMedCentralCrossRefPubMed
79.
Murray JT, Campbell DG, Peggie M, Mora A, Cohen P: Identification of filamin C as a new physiological substrate of PKBalpha using KESTREL. The Biochemical journal. 2004, 384 (Pt 3): 489-494.PubMedCentralCrossRefPubMed
80.
Peng C, Knebel A, Morrice NA, Li X, Barringer K, Li J, Jakes S, Werneburg B, Wang L: Pim kinase substrate identification and specificity. Journal of biochemistry. 2007, 141 (3): 353-362. 10.1093/jb/mvm040.CrossRefPubMed
81.
Huang HD, Lee TY, Tzeng SW, Horng JT: KinasePhos: a web tool for identifying protein kinase-specific phosphorylation sites. Nucleic acids research. 2005, W226-229. 10.1093/nar/gki471. 33 Web Server
82.
Senawongse P, Dalby AR, Yang ZR: Predicting the phosphorylation sites using hidden Markov models and machine learning methods. Journal of chemical information and modeling. 2005, 45 (4): 1147-1152. 10.1021/ci050047+.CrossRefPubMed
83.
Wong YH, Lee TY, Liang HK, Huang CM, Wang TY, Yang YH, Chu CH, Huang HD, Ko MT, Hwang JK: KinasePhos 2.0: a web server for identifying protein kinase-specific phosphorylation sites based on sequences and coupling patterns. Nucleic acids research. 2007, W588-594. 10.1093/nar/gkm322. 35 Web Server
84.
Niedner RH, Buzko OV, Haste NM, Taylor A, Gribskov M, Taylor SS: Protein kinase resource: an integrated environment for phosphorylation research. Proteins. 2006, 63 (1): 78-86. 10.1002/prot.20825.CrossRefPubMed
85.
Petretti C, Prigent C: The Protein Kinase Resource: everything you always wanted to know about protein kinases but were afraid to ask. Biology of the cell/under the auspices of the European Cell Biology Organization. 2005, 97 (2): 113-118.CrossRefPubMed
86.
Smith CM: The protein kinase resource and other bioinformation resources. Progress in biophysics and molecular biology. 1999, 71 (3-4): 525-533. 10.1016/S0079-6107(98)00046-7.CrossRefPubMed
87.
Smith CM, Shindyalov IN, Veretnik S, Gribskov M, Taylor SS, Ten Eyck LF, Bourne PE: The protein kinase resource. Trends in biochemical sciences. 1997, 22 (11): 444-446. 10.1016/S0968-0004(97)01131-6.CrossRefPubMed
88.
MacDonald JA, Mackey AJ, Pearson WR, Haystead TA: A strategy for the rapid identification of phosphorylation sites in the phosphoproteome. Mol Cell Proteomics. 2002, 1 (4): 314-322. 10.1074/mcp.M200002-MCP200.CrossRefPubMed
Metadata
Title
Novel molecular imaging platform for monitoring oncological kinases
Authors
Shyam Nyati
Brian D Ross
Alnawaz Rehemtulla
Mahaveer S Bhojani
Publication date
01-12-2010
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2010
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/1475-2867-10-23

Other articles of this Issue 1/2010

Cancer Cell International 1/2010 Go to the issue

Primary research

Bradykinin increases resensitization of purinergic receptor signaling in glioma cells

Editorial

Reflections on the responsible conduct of cancer research

Primary research

Morphologic transformation of human breast epithelial cells MCF-10A: dependence on an oxidative microenvironment and estrogen/epidermal growth factor receptors

Primary research

ASPM-associated stem cell proliferation is involved in malignant progression of gliomas and constitutes an attractive therapeutic target

Primary research

Epigenetic regulator MLL2 shows altered expression in cancer cell lines and tumors from human breast and colon

Primary research

A natural compound from Hydnophytum formicarium induces apoptosis of MCF-7 cells via up-regulation of Bax
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits